IoT’s Influence On Asia’s Manufacturing Sector In 2023 – Go Health Pro

IoT’s Influence On Asia’s Manufacturing Sector In 2023 – Go Health Pro

“Despite supply headwinds, labour shortages, and an uncertain economic environment, the manufacturing industry continues to surpass the expectations of previous years. To maintain this growth, leaders should leverage digital technologies, adopt strategies for the future of work, and drive supply chain resiliency.” Deloitte The Deloitte report, 2023 manufacturing industry outlook, predicts that manufacturers will likely … Read more

Toward a universal treaty on ‘Protection of Persons in the Event of Disasters’ – EJIL: Talk! – Go Health Pro

Toward a universal treaty on ‘Protection of Persons in the Event of Disasters’ – EJIL: Talk! – Go Health Pro

On Wednesday 6th December, the UN General Assembly adopted by consensus resolution A/C.6/79/L.16 submitted by the UNGA Sixth Committee (here). Based on this resolution, the UNGA has decided to ‘elaborate and conclude a legally binding instrument on the protection of persons in the event of disasters, without prejudice to the legal effects of any particular provisions contained therein, by the end of 2027 at the latest’ (OP 4). With its adoption, the UNGA has thus paved the way for negotiations on a universal treaty on the international legal framework relevant to disasters, based on the draft articles of the International Law Commission (ILC DAs) adopted in 2016. This contribution will focus on the long journey of the ILC DAs towards a treaty, the next steps and the legal issues that will be at the centre of the upcoming negotiations among States.

A long way from the 2004 tsunami to the future treaty

Read more

Zacks Small Cap Research – MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial… – Go Health Pro

Zacks Small Cap Research – MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial… – Go Health Pro

By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from the 16-week Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The trial had two parts: … Read more

x